A Comprehensive View of Global Bio... BIX 2022 Opens Offline After 3 Years

[Asia Economy Reporter Chunhee Lee] BIOPLUS-INTERPHEX KOREA 2022 (BIX) will open offline for the first time in three years. From the 3rd to the 5th of next month, it is expected that 40 sessions, 120 speakers, 200 companies, and about 10,000 attendees will participate over three days.

On the morning of the first day, the 3rd, the opening ceremony will be held with the participation of Go Han-seung, Chairman of the Korea Bio Association, Jang Young-jin, 1st Vice Minister of the Ministry of Trade, Industry and Energy, Michelle McMurry Heath, President of the American Bio Association, Jovita Neliupsiene, Vice Minister of the Ministry of Economy and Innovation of Lithuania, and Son Joo-beom, CEO of Reed Exhibitions Korea.

Following this, the first keynote session titled "Drawing the Present and Future of the Korean Bio Industry 2022" will highlight the necessary changes in the ecosystem for the success of the Korean bio industry from three major perspectives. ▲Hwang Man-soon, CEO of Korea Investment Partners, will discuss bio funding and investment, ▲Lee Jung-kyu, CEO of Bridge Biotherapeutics, will cover the bio venture sector, and ▲Choi Yoon-hee, Senior Research Fellow at the Korea Institute for Industrial Economics and Trade, will address government, policy, and public sectors, presenting their arguments accordingly.

Next, in the second professional session titled "Are Bio Companies a 'Bubble'?", a self-reflection on the valuation of bio companies will take place. Recently, voices from various sectors have criticized bio companies for not realistically recognizing current problems, but since it remains difficult to evaluate the potential for future growth, this session was organized under the judgment that a practical measurement of the current value of bio companies is urgently needed across accounting, investment, and other fields.

Lee Seung-gyu, Executive Vice Chairman of the Bio Association, will serve as the moderator and seek advice on the current reality from the bio industry’s perspective. Through the voices of Jo Wan-seok, accountant at The All Accounting Firm who has advised on IPO strategies for bio and healthcare companies, and Seo Yong-beom, PWC partner who has advised bio companies with unstable financial conditions on IPO preparations, attendees will be able to observe differences in perspectives on the value of bio companies from an accountant’s viewpoint.

Kang Ji-soo, Executive Director of BNH Investment, will present an analysis of the valuation issues from a venture capital (VC) perspective and its correlation with the increased barriers to IPO entry. Yoo Hyo-sang, President of Unicorn Management Economics Institute, will provide clear insights on the market’s view of bio company value based on startup founding research. Lee Won-guk, Deputy Director of the Corporate Growth Support Team at the Korea Exchange, will pinpoint the reasons why bio companies actually face difficulties in going public. Top venture capital investors, accountants, and stock exchange experts from the industry will gather to provide an opportunity to confront the current realities faced by Korean bio companies today.

Information on BIX 2022 sessions, speakers, exhibiting companies, and pre-registration can be found on the official website. Additionally, detailed information is available through the Bio Association’s website, LinkedIn, Facebook, and Instagram.

This content was produced with the assistance of AI translation services.